Theriva Biologics soars after cancer drug meets main goal in mid-stage trial

Theriva Biologics

07/05/2025 12:29

** Shares of cancer therapy developer Theriva Biologics TOVX.A rise 80% to $2.45 premarket

** Co says its experimental cancer drug, zabilugene almadenorepvec, when used with chemotherapy, met the main goal of improved overall survival and reduced risk of disease progression, in a mid-stage trial

** Patients who received the drug with standard chemotherapy lived longer, 10.8 months, compared to those who received only chemotherapy, 8.6 months - TOVX

** The drug was being tested in first-line treatment of metastatic pancreatic ductal adenocarcinoma – a type of cancer that starts in the ducts of the pancreas and has spread to other parts of the body

** Co says the drug has been tested in over 140 patients and was well-tolerated

** As of last close, stock down 22.3% YTD

(Reporting by Kamal Choudhury in Bengaluru)

((Kamal.Choudhury@thomsonreuters.com;))